NasdaqGS:REGNBiotechs
How WHO’s Maftivimab Priority for Bundibugyo Trials At Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story
Regeneron Pharmaceuticals recently reported that maftivimab, a key antibody in its FDA-approved Ebola therapy Inmazeb, was prioritized by the World Health Organization’s Therapeutics Advisory Group for evaluation in clinical trials targeting Bundibugyo ebolavirus amid an ongoing outbreak in Central and East Africa.
This WHO prioritization, combined with Regeneron’s existing Inmazeb stockpiles and history of compassionate use and donations, underscores the company’s growing role in global...